Milestone Scientific Receives Buy Rating from Maxim Group with $2.00 Price Target.

Milestone Scientific (MLSS) has received a Buy rating from Maxim Group with a price target of $2.00. The company's shares opened at $0.62. Analysts have a Moderate Buy consensus with a price target consensus of $1.25. The latest earnings release reported a quarterly revenue of $2.23 million and a GAAP net loss of $1.99 million. Corporate insider activity shows negative sentiment with an increase in insiders selling shares in the past quarter.

Milestone Scientific (MLSS), a medical device company, reported its Q2 2025 financial results, revealing a slight earnings miss and a revenue shortfall against forecasts. The company’s earnings per share (EPS) came in at a loss of $0.02, compared to the forecasted loss of $0.01. Revenue reached $2.3 million, falling short of the $2.6 million forecast [1].

Despite the revenue miss, the company’s stock experienced a premarket increase of 4.73%, trading at $0.6066, following a post-market decline of 3.77% to $0.5792. The company maintains a healthy gross profit margin of 74.37%, though it’s currently not profitable [1].

Key Takeaways
- Revenue for Q2 2025 was $2.3 million, a 25% increase year-over-year.
- The EPS loss was slightly higher than forecasted, at $0.02 versus $0.01.
- Stock price rose 4.73% in premarket trading after an initial decline post-earnings.
- International sales contributed significantly, representing 48% of total revenue.

Market Reaction
Following the earnings release, Milestone Scientific’s stock initially declined by 3.77% in after-hours trading, closing at $0.5792. However, the stock rebounded in premarket trading, rising 4.73% to $0.6066. This positive movement suggests investor optimism about the company’s strategic initiatives and potential market expansion despite the earnings miss [1].

Analyst Ratings
Milestone Scientific has received a Buy rating from Maxim Group with a price target of $2.00. The company's shares opened at $0.62. Analysts have a Moderate Buy consensus with a price target consensus of $1.25. The latest earnings release reported a quarterly revenue of $2.23 million and a GAAP net loss of $1.99 million [2].

Outlook
The company remains focused on disciplined execution to accelerate adoption in the medical and dental segments. Milestone Scientific is investing in reimbursement data collection and expanding distribution partnerships, with potential growth in the VA and international markets. Future EPS forecasts indicate a gradual improvement, with expectations to narrow losses in upcoming quarters [1].

References:
[1] https://za.investing.com/news/transcripts/earnings-call-transcript-milestone-scientifics-q2-2025-revenue-falls-short-93CH-3842785
[2] https://za.investing.com/news/transcripts/earnings-call-transcript-milestone-scientifics-q2-2025-revenue-falls-short-93CH-3842785